SANTONI, MEDARDO
SANTONI, MEDARDO
Personale tecnico amm.vo
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis
2021 Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Ricci A.D.; Grilli G.; Greco A.; Montironi R.; Ardizzoni A.; Massari F.
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials
2021 Massari F.; Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Ardizzoni A.; Santoni M.
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials
2021 Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Rosellini M.; Marchetti A.; Montironi R.; Ardizzoni A.; Massari F.
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review
2021 Rizzo A.; Mollica V.; Dall'Olio F.G.; Ricci A.D.; Maggio I.; Marchetti A.; Rosellini M.; Santoni M.; Ardizzoni A.; Massari F.
Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough
2021 Mollica V.; Brocchi S.; Dall'olio F.G.; Marcolin L.; Paccapelo A.; Santoni M.; Rizzo A.; Montironi R.; Golfieri R.; Massari F.; Ardizzoni A.
The human microbiota and prostate cancer: Friend or foe?
2019 Massari, F.; Mollica, V.; Di Nunno, V.; Gatto, L.; Santoni, M.; Scarpelli, M.; Cimadamore, A.; Lopez-Beltran, A.; Cheng, L.; Battelli, N.; Montironi, R.; Brandi, G.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis | Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Ricci A.D.; Grilli G.; Greco A.; Mo...ntironi R.; Ardizzoni A.; Massari F. | 2021-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials | Massari F.; Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Ardizzoni A.; Santoni M. | 2021-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials | Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Rosellini M.; Marchetti A.; Montironi R.; Ardizzoni... A.; Massari F. | 2021-01-01 | EUROPEAN UROLOGY FOCUS | - | 1.01 Articolo in rivista | - |
| Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review | Rizzo A.; Mollica V.; Dall'Olio F.G.; Ricci A.D.; Maggio I.; Marchetti A.; Rosellini M.; Santoni ...M.; Ardizzoni A.; Massari F. | 2021-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough | Mollica V.; Brocchi S.; Dall'olio F.G.; Marcolin L.; Paccapelo A.; Santoni M.; Rizzo A.; Montiron...i R.; Golfieri R.; Massari F.; Ardizzoni A. | 2021-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-13-03492-v3.pdf |
| The human microbiota and prostate cancer: Friend or foe? | Massari, F.; Mollica, V.; Di Nunno, V.; Gatto, L.; Santoni, M.; Scarpelli, M.; Cimadamore, A.; Lo...pez-Beltran, A.; Cheng, L.; Battelli, N.; Montironi, R.; Brandi, G. | 2019-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-11-00459.pdf |